Aarti Drugs Ltd Q2 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/tp18xb3jys4ph2eju4xinla6.pdf

Key Takeaways


Pricing & Demand Environment

Adhish Patil: "So it has more or less stabilized. However, I would like to point out that in certain antibiotic products, we are still seeing a slight decline in selling prices as we start the current December quarter."

Salicylic Acid: The Turnaround Bet

Adhish Patil: "So we are thinking of going ahead to have capacity for salicylates in case we are not able to make money in salicylic acid, then definitely salicylates will definitely make more money."

Regulatory Milestones & Formulation Business

Adhish Patil: "In fact, in the closing meeting we did ask him, what they feel about the API facility. So he was like, it is like any other API facility, any other API facility. So that way he was not negative about it. But nevertheless, they did tell us that you give a very strong CAPA cover for this within 15 days, and it might get through."

Capex Cycle & Capacity Build-Out


Segment & Product Dynamics

Adhish Patil: "Even now, it is growing at a good pace. So we are committed to this particular product. So we think the future is better than rest of the products for this particular product."

Margins & Profitability

Adhish Patil: "Probably may not look very good. I'm not saying -- but it will bring a lot of clarity to the table that how things will shape up in the future."

Guidance & Commitments

CommitmentSpecificsTimeline
Salicylic acid production ramp-upReach 200-300 tons per monthNovember 2024 (internally targeted)
Salicylic acid capacity ramp-upRamp to 300-plus tons per monthBy end of December quarter (Q3 FY25)
Derma facility breakevenStreamline production, eliminate negative impactNovember 2024
Derma facility profitabilityTurn profitable at 700-800 tons per monthOnce throughput achieved (no date)
Saykha greenfield CWIP capitalizationPlant to go online, capitalize CWIPDecember quarter (Q3 FY25), at max Q4 FY25
Total FY25 capexRoughly INR200 croresFull year FY25
Move out of INR65-70 crores EBITDA rangeExit the 9-10 quarter rangeFrom Q4 FY25 onwards
Revenue potential (revised guidance)INR3,500-4,000 crores2-3 year timeline from now
US FDA regulatory outcomeAwait response to CAPA submissionSubmitted within 15 working days of audit; timeline for agency response not specified
Old formulation projects commercial supplyStart commercial supply6 months' time
Formulation business pickupPick up on strong order book of more than $12 millionComing 2-3 quarters
Long-term EBITDA margin target15% to 15.5%Long term (no specific date)

Key Metrics

MetricQ2 FY25
Standalone revenue₹543.1 cr, down 6% YoY from ₹577.5 cr
Domestic/export mix66% domestic, 34% export
EBITDA₹68.5 cr, margin at 11.5%
PAT₹35 cr
Formulation segment revenue₹65.6 cr, exports contribution 53%
H1 FY25 formulation revenue₹136.6 cr
API segment utilization78% for the September quarter
YoY price variance (API)negative 7%–8%
QoQ price variance (composite)negative 0.5% versus June quarter
Salicylic Acid production~100 tons per month, capacity of 1,800 metric tons per month
Salicylic Acid PBT impact₹5.5 cr negative impact at bottom line from lower production and unabsorbed overheads
Metformin sales volumemore than 1,000–1,200 tons per month
Metformin capacity1,350–1,400 tons per month
H1 FY25 capex incurred~₹90 cr
Full-year FY25 capex guidance~₹200 cr, through internal accruals and partly term loans
Outstanding CWIPslightly less than ₹300 cr, expected to transfer to fixed assets by Q3 or Q4 FY25
Derma facility depreciation and interest hit₹3.5 cr–₹4 cr per quarter
Formulation export order bookmore than $12 million
US FDA audit observations7 observations, response submitted within 15 working days
Long-term EBITDA target15%–15.5%
Revised revenue potential guidance₹3,500 cr–₹4,000 cr by FY27, down from earlier ₹4,200 cr–₹4,500 cr
Standalone revenue potential at current pricing and capacity₹2,750 cr (API plus spec chem, excluding greenfield projects)
Buyback completed665,000 equity shares at ₹900 per share, face value ₹10 each